GeneDx Q2 2023: Exome/genome revenue up 36% YoY; cash burn down 36%

GeneDx Holdings Corp.

2023-Q2 EPS reported -$4.73 revenue$91,845,000

Continuing ops revenue $45.2M (+13% YoY); exome/genome rev. $28.7M (+36% YoY).
Exome/genome volume 11,900 tests (+56% YoY); total tests ~55,000.
Adj. gross margin 37% (pro forma), up from 34% in Q1; total adj. gross margin 42%.
Adj. net loss $41.8M, improved 37% YoY; cash burn $53M, improved 36% YoY.
FY2023 revenue guidance reaffirmed $205-220M; H2 cash use $70-85M; profitability target 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

GeneDx Holdings Corp. reported the second quarter of 2023 results: revenue $48.7 million, net income $46.7 million. Guidance reaffirmed.

Period: the second quarter of 2023
Revenue: $48.7 million
Net income: $46.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

net loss for the second quarter of 2023 was $41.8 million 2 , an improvement of 37% year-over-year and 17% sequentially. · Revenue 1 : Revenue for the second quarter of 2023 was $48.7 million, compared to $36.2 million in the second quarter of 2022. · Gross Margin 1 : Gross margin for the second quarter of 2023 was 39%. Adjusted gross margin for the second quarter of

View on SEC.gov

Browse all earnings releases →

GeneDx Holdings Corp. filing history →

Source: SEC EDGAR

accession 0001818331-23-000060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.